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Pneumococcal surface protein A (PspA) elicits protection in mice against
fatal bacteremia and sepsis caused by genetically diverse pneumococci and
protects against carriage and lung infection. We determined the PspA fami-
lies of invasive isolates of  Streptococcus pneumoniae recovered from
Colombian children <5 years of age. That 97.5% of Colombian isolates
belong to PspA families 1 and 2 supports the hypothesis that a human PspA
vaccine covering a few PspA families could be broadly effective.
Streptococcus pneumoniae is a major respiratory patho-
gen that also causes meningitis, otitis media, and bacteremia
(1). In adults, capsular polysaccharides of S. pneumoniae can
elicit protective antibodies against pneumococcal infection
(2). However, in children <2 years of age polysaccharide vac-
cines do not effectively elicit a protective response (3,4), and
children can have repeated infections with strains of the
same or different capsular serotype (5). Therefore, protein-
polysaccharide conjugates and pneumococcal proteins,
including pneumolysin, neuraminidase, pneumococcal sur-
face adhesin A, and pneumococcal surface protein A (PspA),
have been considered as alternative means to induce protec-
tive immunity in infants and children. The increased fre-
quency of isolation of multidrug-resistant strains of  S.
pneumoniae accentuates the need for an effective vaccine (6).
PspA, a surface protein and virulence factor found on all
isolates of S. pneumoniae (7), is highly immunogenic (6-8).
PspAs share many cross-reactive epitopes, and immuniza-
tion with a single PspA is cross-protective in mice against
fatal infection with strains of the mouse virulent capsular
types (6,9,10). Mucosal immunization with PspA can also
elicit immunity to carriage (11,12).
Information about the basic protein structural domains
of PspA came from the DNA sequences of the pspA/Rx1 and
the pspA/EF5668 genes (13,14). The five domains include 1)
a signal peptide, 2) an alpha-helical charged domain (amino
acids 1-288), 3) a proline-rich region (amino acids 289-370),
4) a choline-binding domain consisting of 9 to 10 twenty-
amino-acid repeats (amino acid 371-571), and 5) a C-termi-
nal 17-amino-acid tail (amino acids 572-589). These amino-
acid positions are based on the pspA/Rx1 sequence (14). 
A portion of  pspA/Rx1 (amino acids 192-260) has been
identified that elicits cross-protective antibody responses
(15). Many PspA molecules have been examined to aid in the
development of PspA as a protein-based vaccine (16). From
the alignment of PspA sequences of 24 strains, the sequence
differences in a centrally located clade-defining region were
used to group PspA proteins into six clades (16). Within the
clade-defining region, sequences in the same clade share at
least 80% amino-acid identity. The clade-defining region is
roughly the same as that shown to elicit cross-protective
responses (15,16). The six clades have also been grouped into
three families. Sequences share at least 50% sequence iden-
tity in each family (16).
During the 1990s, the Colombian Pneumococcal Study
Group investigated the capsular type distribution and anti-
microbial susceptibility of invasive isolates from children <5
years of age (17). The data obtained may guide selection of
polysaccharides to include in vaccines for use in Latin Amer-
ica. In Colombia and other Latin American countries, the
prevalence of strains of capsular serotypes 1 and 5 is higher
than in North America (18,19). The study demonstrated that
vaccine formulations based only on North American data
might not be as effective in Latin America because of the dif-
fering distributions of capsular types. Surveillance of iso-
lates has continued to monitor any shifts in the antigenic
types of pneumococci (20).
Our study was intended to expand our knowledge of vac-
cine coverage for a potential protein-based vaccine in Colom-
bian isolates. We determined the frequency of family 1 and
family 2 PspAs among S. pneumoniae isolates from Colombia
that express one of the seven most common capsular types.
Our results will be coordinated with those from laboratories
in other Latin American countries to learn the diversity of
PspA over the entire region. At present, however, only the
Colombian isolates have been investigated completely.
Materials and Methods
Forty  S. pneumoniae invasive isolates, representing
each year from 1994 through 1998, were selected from the
seven most common capsular types in Colombia. All isolates
were confirmed to be S. pneumoniae by standard procedures
(alpha-hemolysis, Gram stain, optochin test, and bile solubil-
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ity) (21). Antimicrobial susceptibility patterns were not con-
sidered in the selection of isolates.
Pneumococci were cultured for 6 hr in 10 mL Todd-
Hewitt broth (Difco, Detroit, MI) supplemented with 1%
yeast extract, 1% glucose, and 22 µg/mL glutamic acid. After
centrifugation, the cells were resuspended in 0.1 mL TE (10
mM Tris HCL, 1mM EDTA, pH 8.0), and lysozyme (10 µL at
50 mg/mL) was added. The cells were incubated for 30 min at
37ºC, and 0.5 mL GES (5 M guanidine thiocyanate, 0.1 M
EDTA, pH 8.0, and 0.5% sarkosyl) was added. After incuba-
tion at room temperature for 10 min, 0.25 mL (7.5 M) ammo-
nium acetate was added, and the cells were mixed and
placed on ice for 10 min. Chloroform/isoamyl alcohol (24:1)
was added and mixed, the phases were separated by centrif-
ugation, and 0.7 mL of aqueous phase was recovered. The
DNA was precipitated with ethanol and resuspended in 50-
100 µL of TE (22).
Polymerase chain reaction (PCR) was carried out on
genomic DNA. The oligonucleotide primers for family 1 were
LSM12, 5'CCGGATCCAGCGTCGCTATCTTAGGGGCTGGTT3'
(23) and SKH63, 5'TTTCTGGCTCAT(C and T)AACTGCTTTC3'
(at position 12 C and T in a 1:1 ratio) and for family 2 were
LSM12, 5'CCGGATCCAGCGTCGCTATCTTAGGGGCTGGTT3'
and SKH52, 5' TGGGGGTGGAGTTTCTTCTTCATCT3'. The fol-
lowing PCR conditions were used: an initial 95ºC (3 min), 30
cycles of 95ºC (1 min), 62ºC (1 min) and 72ºC (3 min), followed by
72ºC (10 min) (15) in a PTC 150 Thermocycler (MJ Research,
Watertown, MA). PCR products were initially run at an anneal-
ing temperature of 62ºC. Any isolates yielding no product at
62ºC were repeated at annealing temperatures of 65ºC or 58ºC
and then 55ºC to account for potential sequence divergence in
the primer region. The amplified PCR products were approxi-
mately 1,000 bp for family 1 and 1,200 bp for family 2. The PCR
product was run on an agarose gel at 80 volts for 1.5 hr, and the
gel was stained with 0.5 µg/mL ethidium bromide. Molecular
weight standard for gel electrophoresis was the 1.0-kb ladder
DNA (Promega, Madison, WI). Strains BG9739 (clade 1) and
AC122 (clade 3) were used as controls for family 1 and 2 tests,
respectively (16). The PspA family of these strains has been con-
firmed by DNA sequence of their pspA genes (16).
A pool of immune sera for typing PspA families came
from two rabbits, one immunized with rPspA/L82016 (clade
1) and the other with rPspA/Rx1 (clade 2). The antisera for
typing PspA family 2 came from a pool of serum from two
rabbits immunized with either PspA/V-024 (clade 3) or PspA/
V-032 (clade 4). Recombinant PspA/Rx1 was added to this
pool to reduce cross-reactivity with family 1 (clade 1 and 2)
PspAs. 
PspAs were recombinant products from Escherichia coli
strains bearing plasmids with cloned pspA genes. The region
of PspA in the cloned fragment includes the entire alpha-
helical region of the protein and in some cases some of the
proline-rich region, which is C-terminal to the alpha-helical
region. The gene fragments were cloned into pET-20b vector
from Novagen (Madison, WI) between the NcoI and the XhoI
cloning sites. This procedure results in an additional 10
amino acids on the C-terminus of the recombinant protein,
which includes a polyhistidine for purification. Recombinant
proteins were produced in  E. coli strain BL21 (DE3) from
Novagen and purified by nickel-affinity chromatography, as
recommended by the manufacturer. Rabbits were immu-
nized subcutaneously with 10 µg of protein with complete
Freund’s adjuvant, followed by a second 10-µg injection 1
month later with incomplete Freund’s adjuvant and a final
10-µg booster after another month. Rabbits were bled 2
weeks after the last booster.
Pneumococcal isolates were cultured for 6 hr in 10 mL
Todd-Hewitt broth (Difco) supplemented as described. After
centrifugation, cells were resuspended in 3 mL sterile phos-
phate-buffered saline (PBS), and 500 µL lysis buffer (0.1%
sodium deoxycholate, 0.01% sodium dodecyl sulfate, and
0.15M sodium citrate in 100 µL deionized water) was added.
The mixture was incubated at room temperature for 30 min.
Protein in lysates was measured by using bicinchoninic
acid as described by Smith et al. (24) with some modifica-
tions. The lysate samples were diluted 1:3.5 in sterile PBS.
Then, 10 µL of each sample was loaded into a microplate
well (U bottom, Becton-Dickinson, Cockeysville, MD) and
200 µL of a 50:1 mixture of reagent A (bicinchoninic acid
[BCA-SIGMA B9643, Sigma, St. Louis, MO]) and reagent B
(copper [II] sulfate pentahydrate 4% [SIGMA C2284, Sigma])
was added. The microplate was incubated for 30 min and
absorbance at 562 nm (BIO-RAD ELISA reader model 3550,
Hercules, CA) was compared with a protein bovine serum
albumin (BSA) standard curve (1 mg/mL).
After the protein concentration of each lysate was
adjusted to 60 µg/mL, 1 µL of lysate and 1 µL each from dilu-
tions 1:5 (12 µg/mL), 1:25 (2.4 µg/mL), and  <1:125 (0.48 µg/
mL) were spotted onto two nitrocellulose membranes (Milli-
pore, Bedford, MA) for dot-blot analysis. Each membrane
was immersed in 1% BSA/PBST blocking buffer (0.05%
Tween 20, 1 mM EDTA pH 8.5, 1% BSA in sterile PBS, incu-
bated at room temperature for 1 hr, and washed three times
with sterile PBS. Membranes were then immersed in a dilu-
tion of anti-PspA rabbit polyclonal antibodies (1:5,000 in
blocking buffer) and incubated at room temperature for 1 hr.
Rabbit antisera for families 1 and 2 were processed on sepa-
rate dot blots. The membranes were then washed three
times with sterile PBS and incubated with a biotinylated
goat anti-rabbit antibody diluted 1:3,000. The final incuba-
tion was with streptavidin-conjugated alkaline phosphatase
diluted 1:3,000 and incubated for 1 hr, followed by another
washing step. Alkaline phosphatase staining was developed
with NBT solution (2 mg nitroblue tetrazolium, 10 mg BCIP
[5-bromo-4-chloro-3-indolyl phosphate, p-toluidine salt], 200
µL dimethyl sulfoxide in 20 mL Tris HCl, pH 8.8) with con-
stant shaking until control dots appeared purple. Assign-
ment of the serologic dot-blot results was based on the
highest titer of each lysate that reacted with the dilution of
the anti-family 1 and anti-family 2 antiserum. BG9739
(clade 1) and EF10197 (clade 2) were used as reference
strains for serologic family 1 typing. AC122 (clade 3),
BG11703 (clade 4) and ATCC6303 (clade 5) were used as ref-
erence strains for typing family 2 (16).
Results
PCR products ranged from 960 to 1,000 bp for family 1,
and 1,200 to 1,400 bp for family 2 (Figure). Although all
lysates of family 1 strains reacted with the family 1 antise-
rum at 1:5,000 dilution, the antiserum cross-reacted weakly
with family 2 lysates, which could generally be detected at a
<1:25 dilution but not at higher dilutions. The family 2 anti-
serum reacted only with the PspAs of family 2 strains,
regardless of the dilution. Nevertheless, the combination ofResearch
Emerging Infectious Diseases 834 Vol. 7, No. 5, September-October 2001
the two techniques could reliably detect the PspA family of
all strains. The PspA PCR and the PspA serologic dot-blot
techniques correlated in 100% of cases.
Of the 40 isolates studied, 25 (62.5%) were family 1
PspA (Table). Family 1 PspAs were found among isolates
with capsular types 14, 6B, 23F, 5, 19F, 1, 8, and 35. All inva-
sive isolates capsular type 6B, 5, and 19F were family 1.
Fourteen (35%) isolates were family 2, including strains of
capsular types 14, 23F, 9, 3, 8, and 35. The relative distribu-
tion of family 1 isolates to family 2 isolates did not fluctuate
substantially over the 4-year period. Isolate Co-29, which
was capsular type 1, was the only one (2.5%) of the 40 that
was neither family 1 or family 2. The remaining four isolates
of capsular type 1 were family 1. 
Table. Streptococcus pneumoniae PspA families 1 and 2 from 40 Colombian isolates
Isolates (Code INSa) Date Source Capsular type PCR & dot blot
Co-1(2) 17/12/93 Blood 14 Family 1
Co-2 (125) 12/12/94 CSF 14 Family 2
Co-3 (146) 25/01/95 Blood 14 Family 2
Co-4 (309) 17/01/96 PLF 14 Family 1
Co-5 (E-212) 16/06/98 CSF 14 Family 2
Co-6 (95) 17/06/93 CSF 6B Family 1
Co-7 (20) 19/06/94 Blood 6B Family 1
Co-8 (149) 04/02/95 CSF 6B Family 1
Co-9 (322) 10/02/96 CSF 6B Family 1
Co-10 (E-10) 03/05/96 Blood 6B Family 1
Co-11(14) 20/04/94 PLF 23F Family 2
Co-12 (23) 22/06/94 CSF 23F Family 2
Co-13 (152) 15/02/95 CSF 23F Family 1
Co-14 (E-8) 03/05/96 CSF 23F Family 1
Co-15 (E-99) 19/03/97 CSF 23F Family 2
Co-16 (7) 25/03/94 PLF 5 Family 1
Co-17 (106) 10/11/94 Blood 5 Family 1
Co-18 (177) 06/04/95 Blood 5 Family 1
Co-19 (316) 24/01/96 Blood 5 Family 1
Co-20 E-220) 24/07/98 CSF 5 Family 1
Co-21(10) 25/04/94 CSF 19F Family 1
Co-22 (179) 08/04/95 CSF 19F Family 1
Co-23 (318) 27/01/96 Blood 19F Family 1
Co-24 (E-124) 04/07/97 CSF 19F Family 1
Co-25 (E-159) 23/10/97 CSF 19F Family 1
Co-26 (5) 19/03/94 Blood 1 Family 1
Co-27 (99) 04/11/93 CSF 1 Family 1
Co-28 (165) 01/03/95 Blood 1 Family 1
Co-29 (315) 26/01/96 PLF 1 0b
Co-30 (E-107) 16/04/97 Blood 1 Family 1
Co-31(51) 04/09/94 PLF 9V Family 2
Co-32 (E-24) 14/06/96 CSF 9N Family 2
Co-33 (119) 25/11/94 Blood 3 Family 2
Co-34 (E-140) 02/09/97 CSF 3 Family 2
Co-35 (216) 06/06/95 Blood 8 Family 2
Co-36 (E-135) 13/08/97 CSF 8 Family 1
Co-37 (E-66) 07/11/96 CSF 4 Family 2
Co-38 (300) 18/12/95 Blood 35B Family 1
Co-39 (E-25) 14/06/96 CSF 35B Family 2
Co-40 (320) 06/02/96 CSF 35F Family 2
aINS = Instituto Nacional de Salud; PCR = polymerase chain reaction; CSF = cerebrospinal fluid; PLF = pleural fluid.
bCo-29 did not amplify or react with either family.
Figure. Polymerase chain reaction for PspA families 1 and 2: lanes 1 and 2 were controls for families 1 and 2, respectively. Lanes 3 to 7 and 9 (Co-24, Co-25, Co-
26, Co-27, Co-28, Co-29, Co-30 isolates) were family 1. Lane 8 (Co-29) did not amplify with either family. The molecular weight was 1-kb ladder DNA
(Promega).Research
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Conclusion
A vaccine composed of PspA is hypothesized to protect
against invasive disease and also eliminate the carriage
state. Yamamoto et al. (25) reported that intranasal adminis-
tration of PspA in mice together with a nontoxic adjuvant
(mCT S61F) is an effective mucosal vaccine against pneumo-
coccal infection. In another study, active immunization with
PspA reduced the signs of purulent otitis media in rats,
although the challenge strain contained a PspA that differed
from the immunogen (26). More recently, immune sera from
human volunteers immunized with PspA protected against
fatal pneumococcal infection in mice (27).
All the Colombian isolates were invasive, and all but one
belonged to PspA families 1 or 2. This finding is relevant to
efforts to develop PspA into a human vaccine component.
The distribution of the Colombian isolates between PspA
families 1 and 2 did not differ substantially from that
observed for isolates from North America and Europe (16).
Therefore, a vaccine formulation including these two fami-
lies might cover isolates from both North and South America
with equal effectiveness. Latin America has a varied distri-
bution of capsular serotypes (17-19), which lessens the
potential for effectiveness of the heptavalent conjugate vac-
cine recently approved in the United States (28). 
We have obtained information about pulsed-field gel
electrophoresis and penicillin-binding protein patterns and
capsular types of Colombian strains with diminished suscep-
tibility to penicillin (20,29,30). Characterizing PspA families
of these penicillin-resistant strains and examining represen-
tatives of different multiresistant international clones will
be of interest for future studies.
Acknowledgments
We thank J. King, A. Swift, S. Chambers, and M. Golden for
teaching us the techniques required for this study and H. Roch for
careful reading of the manuscript.
This work was partially funded through the Gorgas Memorial
Institute and from the U. S. Agency for International Development
through the Harvard Institute for International Development. Addi-
tional financial support was provided by the Pan American Health
Organization and the Canadian International Development Agency.
Ms. Vela is a scientific investigator in the Microbiology Group
at Instituto Nacional de Salud in Bogotá, Colombia. Her research
interests focus on resistant and multidrug-resistant Streptococcus
pneumoniae recovered from children <5 years of age.
References
  1. Hoges RG, MacLeod CM. Epidemic pneumococcal pneumoniae.
I. Description of the epidemic. Am J Hyg 1946;44:183-92.
  2. Klein JO, Teele DW, Sloyer JL, Ploussard JH, Howie V, Makela
PH, et al. Use of pneumococcal vaccine for prevention of recur-
rent episodes of otitis media. In: Robbins JB, Sadoff JC, editors.
Bacterial vaccines. New York: Thime-Stratton Press; 1982. p.
305-10.
  3. Cowan MJ, Ammann AJ, Wara DW, Howie VM, Schultz L,
Doyle N, et al. Pneumococcal polysaccharide immunization in
infants and children. Pediatrics 1978;62:721-7.
  4. Sniadack DH, Schwartz B, Lipman H. Potential interventions
for the prevention of childhood pneumoniae: geographic and
temporal differences in serotype and serogroup distribution of
sterile site pneumococcal isolates from children-implications for
vaccine strategies. Pediatr Infect Dis J 1995;14:503-10.
  5. Gray BM, Dillion HC, Briles DE. Epidemiological studies of
Streptococcus pneumoniae in infants: development of antibody
to phosphocholine. J Clin Microbiol 1983;18:1102-7.
  6. Briles DE, Creech T, Swiartlo E, Dillard JP, Smith P, Benton
KA, et al. Pneumococcal diversity: considerations for new vac-
cine strategies with emphasis on pneumococcal surface protein
A (PspA). Clin Microbiol Rev 1998;11:645-57.
  7. McDaniel LS, Yother J, Vijayakumar M, McGarry L, Guild WR,
Briles DE. Use of insertional inactivation to facilate studies of
biological properties of pneumococcal surface protein A (PspA).
J Exp Med 1987;165:381-94.
  8. Crain MJ, Waltman II WD, Turner JS, Yother J, Talkington DF,
McDaniel LS, et al. Pneumococcal surface protein A (PspA) is
serologically highly variable and is expressed by all clinically
important capsular serotypes of  Streptococcus pneumoniae.
Infect Immun 1990;58:3293-9.
  9. McDaniel LS, Scott G, Kearney JF, Briles DE. Monoclonal anti-
bodies against protease-sensitive pneumococcal antigens can
protect mice from fatal infection with Streptococcus pneumo-
niae. J Exp Med 1984;160:386-97.
10. McDaniel LS, Sheffield JS, Delucchi P, Briles DE. PspA, a sur-
face protein of  Streptococcus pneumoniae, is capable of eliciting
protection against pneumococci of more than one capsular sero-
type. Infect Immun 1991;59:222-8.
11. Briles DE, Ades E, Paton JC, Sampson JS, Carlone JM, Hueb-
ner RC, et al. Intranasal immunization of mice with a mixture
of the pneumococcal proteins PsaA and PspA is highly protec-
tive against nasopharyngeal carriage of Streptococcus pneumo-
niae. Infect Immun 2000;68:796-800.
12. Wu H-Y, Nahm M, Guo Y, Russell M, Briles DE.  Intranasal
immunization of mice with PspA (pneumococcal surface protein
A) can prevent intranasal carriage and infection, and sepsis
with Streptococcus pneumoniae. J Infect Dis 1997;175:893-6.
13. McDaniel LS, McDaniel DO, Hollingshead SK, Briles DE. Com-
parison of the PspA sequence from Streptococcus pneumoniae
EF5668 to the previously identified PspA sequence from strain
Rx1 and ability of PspA from EF5668 to elicit protection
against pneumococci of different capsular types. Infect Immun
1998;66:4748-54.
14. Yother J, Briles DE. Structural properties and evolutionary
relationships of PspA, a surface protein of Streptococcus pneu-
moniae, as revealed by sequence analysis. J Bacteriol
1992;174:601-9.
15. McDaniel LS, Ralph BA, McDaniel DO, Briles DE. Localization
of protection-eliciting epitopes on PspA of  Streptococcus pneu-
moniae between amino acid residues 192 and 260. Microb
Pathog 1994;17:323-37.
16. Hollingshead SK, Becker R, Briles DE. Diversity of PspA:
mosaic genes and evidence for past recombination in Strepto-
coccus pneumoniae. Infect Immun 2000;68:5889-900.
17. Di Fabio J-L, Homma A, De Quadros C. Pan American Health
Organization epidemiological surveillance network for Strepto-
coccus pneumoniae. Microb Drug Resist 1997;3:131-3.
18. Castañeda E, Leal AL, Castillo O, de la Hoz F, Vela MC, Arango
M, et al. Distribution of capsular types and antimicrobial sus-
ceptibility of invasive isolates of  Streptococcus pneumoniae in
Colombian children. Pneumococcal Study Group in Colombia.
Microb Drug Resist 1997;3:147-52.
19. Kertesz D, Di Fabio JL, Brandileone MC, Castañeda E, Echániz
G, Heitman I, et al. Invasive Streptococcus pneumoniae infec-
tion in Latin-America children: result of the Pan-American
Health Organization surveillance study. Clin Infect Dis
1998;26:1355-61.
20. Vela MC, Fonseca N, Di Fabio JL, Castañeda E. Presence of
international multiresistant clones of  Streptococcus pneumo-
niae in Colombia. Microb Drug Resist. In press 2001.
21. Facklam RR, Washington JA II. Streptococcus and related cata-
lase-negative Gram positive cocci. In: Balows A, Hausler WJ Jr,
Hermann KL, Isenberg HD, Shadomy HJ, editors. Manual of
clinical microbiology. 5th ed. Washington: American Society for
Microbiology; 1991:238-57.
22. Pitcher DG, Saunders NA, Owen RJ. Rapid extraction of bacte-
rial genomic DNA with guanidium thyocyanate. Lett Appl
Microbiol 1989;8:151-6.Research
Emerging Infectious Diseases 836 Vol. 7, No. 5, September-October 2001
23. Swiatlo E, Brooks-Walter A, Briles DE, McDaniel LS.  Oligonu-
cleotides identify conserved and variable regions of pspA and
pspA-like sequences of  Streptococcus pneumoniae. Gene
1997;188:279-84.
24. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH,
Provenzano MD, et al. Measurement of protein using bicin-
chonicic acid. Anal Biochem 1985;150:76-85.
25. Yamamoto M, Briles DE, Yamamoto S, Ohmura M, Kiyono H,
McGhee JR. A nontoxic adjuvant for mucosal immunity to
pneumococcal surface protein A. J Immunol 1998;161:4115-21.
26. White P, Hermansson A, Svanborg C, Briles DE, Prellner K.
Effects of active immunization with a pneumococcal surface
protein (PspA) and of locally applied antibodies in experimental
otitis media. ORL J Otorhinolaryngol Relat Spec 1999;4:206-
11.
27. Briles DE, Hollingshead SK, King JE, Swift A, Braun P, Fergu-
son LM, et al. Immunization of human volunteers with recom-
binant PspA elicits antibodies that passively protect mice. ORL
J Otorhinolaryngol Relat Spec 1999;4:206-11.
28. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR,
et al. Efficacy, safety and immunogenicity of heptavalent pneu-
mococcal conjugate vaccine in children. Northern California
Kaiser permanent vaccine study center group. Pediatr Infect
Dis J 2000;22:187-95.
29. Castañeda E, Peñuela I, Vela MC, the Colombian Pneumococcal
Study Group, Tomasz A. Penicillin-resistant  Streptococcus
pneumoniae in Colombia: presence of international epidemic
clones. Microb Drug Resist 1998;4:233-9.
30. Tomasz A, Corso A, Severina EP, Echaniz-Aviles G, Brandile-
one MC, Camou T, et al. Molecular epidemiologic characteriza-
tion of penicillin-resistant  Streptococcus      pneumoniae
invasive pediatric isolates recovered in six Latin-American
countries: an overview. PAHO/Rockefeller University Work-
shop. Microb Drug Resist 1998;4:195-207. 